A large number of complementary and herbal medicines, cough and throat lozenges and pastilles are authorised in the course of a year.
The newly authorised medicines, excluding authorisations from the notification procedure, can be found in the Swissmedic Journals from the respective year.
All information about the medicinal products reflects the situation on the respective date of authorisation. The current medicinal product information for authorised medicinal products can be found at
A report providing detailed information about the authorisation of complementary and herbal medicines, including details of the authorisation procedures used and statistical evaluations, is also available as of 2021 under Overview.
First-time authorisation of a herbal medicinal product with orphan drug status
The KPA Division’s report provides an overview of complementary and herbal medicinal products newly authorised in 2025 and highlights trends in the number of authorisations across the respective therapeutic areas.
While the number of authorised herbal medicinal products continued to decline, authorisations for homeopathic and anthroposophic medicinal products remained largely stable. Overall, 11 new complementary and herbal medicinal products were authorised in the reporting year, including 5 with an indication. Of particular note is the first-time authorisation of a herbal medicinal product with orphan drug status, representing a significant milestone in the treatment of rare diseases.
Furthermore, the Swiss population continues to have access to a broad range of complementary medicinal products without indication authorised through the notification procedure. Progress in digitalisation and intensified exchange with stakeholders characterised the year 2025.
